Physicochemical Properties
Molecular Formula | C16H31BRO2 |
Molecular Weight | 335.32 |
Exact Mass | 334.15 |
Elemental Analysis | C, 57.31; H, 9.32; Br, 23.83; O, 9.54 |
CAS # | 18263-25-7 |
PubChem CID | 82145 |
Appearance | White to yellow solid |
Density | 1.1±0.1 g/cm3 |
Boiling Point | 403.4±18.0 °C at 760 mmHg |
Melting Point | 52-54 °C |
Flash Point | 197.8±21.2 °C |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.480 |
LogP | 7.76 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 14 |
Heavy Atom Count | 19 |
Complexity | 207 |
Defined Atom Stereocenter Count | 0 |
SMILES | CCCCCCCCCCCCCCC(C(=O)O)Br |
InChi Key | DPRAYRYQQAXQPE-UHFFFAOYSA-N |
InChi Code | InChI=1S/C16H31BrO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(17)16(18)19/h15H,2-14H2,1H3,(H,18,19) |
Chemical Name | 2-bromohexadecanoic acid |
Synonyms | 2-bromopalmitate; 2-BP; 2-Bromopalmitate; 2BP; 2-Bromopalmitic acid; 2 BP; 2 Bromopalmitate; 2Bromopalmitate; 2Bromopalmitic acid; 2 Bromopalmitic acid; |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | After GSDME-N is cleaved, palmitoylation encourages the release of GSDME-C, whereas 2-BP prevents palmitoylation, prevents GSDME-C from being modified, and increases the interaction between GSDME-C and GSDME-N. 2-BP prevents apoptosis brought on by TNFa+CHX, but not complete cell death [1]. |
Cell Assay | For navitoclax or TNFα+CHX treatments, cells were pre-seeded overnight until cell density reached ~60%. The culture medium was switched to fresh medium containing relevant drugs and incubated for a period of time as indicated. To inhibit caspase activity or palmitoylation, cells were pre-incubated for 1 h with Q-VD-OPh or 2-BP, respectively. Unless otherwise specified, the concentrations of the drugs used are: 2 μM for navitoclax, 20 ng/mL for TNFα, 10 μg/mL for CHX, 50 μM for Q-VD-OPh, 50 μM for 2-BP, and 50 μM for actinomycin D [1]. |
References |
[1]. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death Dis. 2020 Apr 24;11(4):281. |
Additional Infomation | 2-bromohexadecanoic acid is a bromo fatty acid that is hexadecanoic (palmitic) acid carrying a single bromo substituent at position 2. It has a role as a fatty acid oxidation inhibitor. It is a bromo fatty acid, a straight-chain fatty acid, a long-chain fatty acid and a 2-bromocarboxylic acid. It is functionally related to a hexadecanoic acid. |
Solubility Data
Solubility (In Vitro) | DMSO : 100 mg/mL (298.22 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9822 mL | 14.9111 mL | 29.8223 mL | |
5 mM | 0.5964 mL | 2.9822 mL | 5.9645 mL | |
10 mM | 0.2982 mL | 1.4911 mL | 2.9822 mL |